Intercell and Romark declare IC41-nitazoxanide syndicate clinical trials on account of HCV
Posted in Disease, Infection on October 20th, 2010Intercell AG (VSE; "ICLL") and Romark Laboratories L.C. today announced plans to inaugurate clinical trials of Intercell’s investigational healthy Hepatitis C virus (HCV) vaccine, IC41, in suspension with Romark’s antiviral medicament, nitazoxanide, during the before all half of 2011.
Intercell’s vaccine possibility has demonstrated a ceaseless reduction of viral worry in long-lasting Hepatitis C (CHC) patients in a Viewpoint Read the rest of this entry »
